GRI net incomeQ2 2026-$1.64M
GRI net income was -$1.64M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$2.89M a year earlier. For the full fiscal 2025 it was -$11.96M, compared with -$8.21M in fiscal 2024.
GRI Bio Inc. (GRI) financials
For the twelve months ended Jun 30, 2026, GRI Bio Inc. reported -$9.66M of net income.
- Net income, TTM
- -$9.66M
- Cash
- $10.95M
- Market cap
- $4.1M
FY2020FY2021
FY2020FY2025
FY2020FY2025
GRI revenue and earnings growth
GRI EPSQ2 2026-$0.91
GRI diluted EPS was -$0.91 in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$121.80.
GRI free cash flowFY2025-$10.19M
GRI free cash flow was -$10.19M for fiscal 2025 (ended Dec 31, 2025), compared with -$8.61M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | $0 | $100.0K |
| Research and development | $6.82M | $3.77M | $3.23M | $242.0K | $5.19M | $3.71M |
| Selling, general and admin | $5.16M | $4.47M | $8.15M | $2.00M | $4.07M | $1.18M |
| Operating income | -$11.98M | -$8.23M | -$11.39M | -$2.24M | -$9.26M | -$4.79M |
| Income tax | $3.0K | $2.0K | - | - | - | - |
| Net income | -$11.96M | -$8.21M | -$13.04M | -$3.22M | -$9.30M | -$4.82M |
| EPS, basic | -$121.80 | -$1545.55 | -$2388610.84 | -$985724.60 | -$1683040.80 | -$1268206.80 |
| EPS, diluted | -$121.80 | -$1545.55 | -$2388610.84 | -$985724.60 | -$1683040.80 | -$1268206.80 |
| Diluted shares | 98,162 | 6,547 | 5.458 | 3.265 | 5.519 | 3.802 |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $8.23M | $5.03M | $1.81M | $9.0K | $90.0K | $109.0K |
| Current assets | $8.59M | $5.62M | $2.93M | $312.0K | $8.13M | $674.0K |
| Total assets | $8.67M | $5.74M | $2.96M | $383.0K | $8.34M | $955.0K |
| Current liabilities | $2.64M | $1.64M | $2.70M | $1.99M | $2.44M | $2.23M |
| Total liabilities | $2.66M | $1.71M | $2.70M | $2.01M | $2.52M | $2.41M |
| Shareholders' equity | $6.01M | $4.03M | $259.0K | -$1.63M | -$4.85M | -$1.45M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$10.19M | -$8.61M | -$8.99M | -$1.08M | -$8.31M | -$3.71M |
| Capital expenditures | $3.0K | $0 | $8.0K | $3.0K | $0 | $2.0K |
| Free cash flow | -$10.19M | -$8.61M | -$9.00M | -$1.09M | -$8.31M | -$3.71M |
| Investing cash flow | -$3.0K | $0 | -$8.0K | -$3.0K | -$3.84M | -$2.0K |
| Financing cash flow | $13.39M | $11.83M | $10.80M | $1.01M | $15.75M | -$4.0K |
| Stock-based compensation | $793.0K | $148.0K | $388.0K | $25.0K | $626.0K | $154.0K |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | - | - | - | -100.0% | - |
| Operating margin | - | - | - | - | - | -4788.0% |
| Net margin | - | - | - | - | - | -4822.0% |
| Free cash flow margin | - | - | - | - | - | -3708.0% |
| Return on equity | -199.0% | -203.5% | -5033.6% | - | - | - |
| Return on assets | -138.0% | -143.0% | -441.0% | -839.9% | -111.6% | -504.9% |
| Current ratio | 3.25 | 3.43 | 1.09 | 0.16 | 3.32 | 0.30 |
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $407.0K | $361.0K | $1.63M | $1.77M | $1.88M | $1.64M | $907.0K | $1.13M | $877.0K | $933.0K | $1.05M | $1.19M |
| Selling, general and admin | $1.24M | $1.64M | $1.03M | $1.60M | $1.02M | $1.41M | $1.05M | $1.00M | $1.38M | $962.0K | $980.0K | $1.25M |
| Operating income | -$1.65M | -$2.00M | -$2.66M | -$3.37M | -$2.90M | -$3.05M | -$1.95M | -$2.13M | -$2.26M | -$1.90M | -$2.03M | -$2.44M |
| Net income | -$1.64M | -$2.00M | -$2.66M | -$3.36M | -$2.89M | -$3.05M | -$1.95M | -$2.12M | -$2.25M | -$1.89M | -$2.00M | -$2.14M |
| EPS, basic | -$0.91 | -$1.61 | - | -$35.84 | -$36.72 | -$162.30 | - | -$319.76 | -$1731.80 | -$48099.80 | - | -$31311.28 |
| EPS, diluted | -$0.91 | -$1.61 | - | -$35.84 | -$36.72 | -$162.30 | - | -$319.76 | -$1731.80 | -$48099.80 | - | -$31311.28 |
| Diluted shares | 1.8M | 1.2M | - | 93,624.929 | 78,757 | 18,768 | - | 6,640.143 | 1,299.25 | 39.212 | - | 68.246 |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $10.95M | $11.05M | $8.23M | $4.05M | $5.12M | $3.28M | $5.03M | $4.75M | $6.35M | $4.09M | $1.81M | $3.49M |
| Current assets | $11.33M | $11.28M | $8.59M | $4.70M | $5.58M | $3.93M | $5.62M | $5.32M | $6.88M | $4.43M | $2.93M | $4.37M |
| Total assets | $11.38M | $11.34M | $8.67M | $4.78M | $5.67M | $4.04M | $5.74M | $5.46M | $7.03M | $4.59M | $2.96M | $4.40M |
| Current liabilities | $1.10M | $794.0K | $2.64M | $2.76M | $2.31M | $2.78M | $1.64M | $1.72M | $2.22M | $1.68M | $2.70M | $2.18M |
| Total liabilities | $1.10M | $794.0K | $2.66M | $2.79M | $2.35M | $2.84M | $1.71M | $1.80M | $2.31M | $1.79M | $2.70M | $2.18M |
| Shareholders' equity | $10.28M | $10.54M | $6.01M | $1.99M | $3.32M | $1.21M | $4.03M | $3.66M | $4.72M | $2.80M | $259.0K | $2.23M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$1.45M | -$3.69M | -$2.97M | -$2.31M | -$3.17M | -$1.74M | -$2.00M | -$2.27M | -$2.14M | -$2.20M | -$5.56M | -$1.31M |
| Capital expenditures | - | - | - | - | - | - | $0 | $0 | - | - | $0 | $0 |
| Free cash flow | - | - | - | - | - | - | -$2.00M | -$2.27M | - | - | -$5.56M | -$1.31M |
| Investing cash flow | - | - | - | - | - | - | $0 | $0 | - | - | $0 | $0 |
| Financing cash flow | $1.34M | $6.50M | $7.15M | $1.25M | $5.01M | -$11.0K | $2.28M | $661.0K | $4.40M | $4.49M | $3.88M | $0 |
| Stock-based compensation | $33.0K | $31.0K | $67.0K | $465.0K | $41.0K | $220.0K | $37.0K | $37.0K | $37.0K | $37.0K | $36.0K | $326.0K |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 10.30 | 14.21 | 3.25 | 1.70 | 2.41 | 1.41 | 3.43 | 3.10 | 3.11 | 2.64 | 1.09 | 2.01 |
Source: XBRL data GRI Bio Inc. files with the SEC, latest filing dated Aug 14, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-30, first reported May 15, 2023; 1-for-83, first reported Aug 14, 2024; 1-for-17, first reported Aug 14, 2025; 1-for-28, first reported Jan 30, 2026.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
GRI peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| GRI | - | - | -$9.66M | - | $4.1M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.27T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $664.95B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $514.92B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $361.71B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $310.17B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $289.10B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $190.39B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $178.51B |
GRI FAQ
4 questionsIs GRI profitable?
No. GRI Bio Inc. reported a net loss of $9.66M for the twelve months ended Jun 30, 2026.How much cash and debt does GRI have?
GRI Bio Inc. reported $10.95M in cash and cash equivalents on its most recent balance sheet in SEC filings.When did GRI last report financial results?
The latest statements here come from GRI Bio Inc.'s 10-Q filed on Aug 14, 2026, covering the period ended Jun 30, 2026.Where does this GRI financial data come from?
Quantisnow builds these statements from the structured XBRL data GRI Bio Inc. files with the SEC. It is provided for information only and is not investment advice.